v3.25.1
Collaboration and license agreements - Narrative (Details)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended
Mar. 31, 2025
USD ($)
performanceObligation
target
Mar. 01, 2024
USD ($)
target
Dec. 11, 2023
USD ($)
target
performanceObligation
May 29, 2023
USD ($)
$ / shares
shares
Sep. 30, 2024
USD ($)
developmentCandidate
Apr. 30, 2024
USD ($)
Mar. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
target
Nov. 30, 2020
USD ($)
target
Feb. 29, 2020
USD ($)
protein
Dec. 31, 2018
USD ($)
performanceObligation
target
Mar. 31, 2025
USD ($)
performanceObligation
target
Mar. 31, 2024
USD ($)
Dec. 31, 2024
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Number of performance obligations | performanceObligation                     12      
Transaction price allocated to performance obligation $ 23,064                     $ 23,064    
Contract with customer, liability 46,702                     46,702   $ 47,169
Revenue from collaboration agreements                       7,238 $ 3,039  
Revenue recognized that was included in the contract liability at the beginning of the period                       5,827 2,744  
Discovery, Regulatory, and Commercial Milestones                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Amount eligible to receive $ 740,000                     $ 740,000    
Minimum                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Written notice period for termination of agreement       90 days                    
MKDG Agreement                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Number of potential research and development targets | target 2 2                   2    
Upfront payment   $ 16,000                        
Number of performance obligations | performanceObligation 2                     2    
Transaction price allocated to performance obligation $ 16,000                     $ 16,000    
Contract with customer, liability 12,306                     12,306   13,373
Revenue from collaboration agreements                       3,153 55  
MKDG Agreement | Minimum                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Written notice period for termination of agreement   60 days                        
Merck Agreement                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Upfront payment     $ 10,000                      
Number of performance obligations | performanceObligation     1                      
Contract with customer, liability 4,892                     4,892   6,022
Option to include number of additional targets | target     3                      
Potential proceeds from collaboration     $ 2,500,000                      
Revenue from collaboration agreements                       1,129 645  
Merck Agreement | Research and development milestones                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Amount eligible to receive     $ 600,000                      
Merck Agreement | Minimum                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Written notice period for termination of agreement     60 days                      
Betta Agreements                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Upfront payment 10,000     $ 10,000                    
Contract with customer, liability 15,007                     15,007   $ 15,281
Stock repurchase program, number of shares authorized to be repurchased (in shares) | shares       5,567,928                    
Stock repurchase program, authorized amount       $ 25,000                    
Share price (in dollars per share) | $ / shares       $ 4.49                    
Stock repurchase program, premium percentage       25.00%                    
Duration of trading day volume weighted average closing price       60 days                    
Trading days prior to the effective date of the Stock Purchase Agreement       2 days                    
Estimated transaction price 135,000                     135,000    
Transaction price from closing of the stock purchase agreement 5,000                          
Regulatory milestone achieved               $ 2,000            
Expected consideration to be received from manufactured clinical supply 118,000                     118,000    
Revenue from collaboration agreements                       460 $ 0  
Betta Agreements | Research and development milestones                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Amount eligible to receive       $ 357,000                    
Betta Agreements | Drug Application Approval                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Amount eligible to receive       $ 40,000                    
Restated Roche Agreement                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Number of targets | target               2 2          
Regulatory milestone achieved             $ 2,000              
Additional upfront consideration received                     $ 40,000      
Number of potential targets | target                 5   6      
Annual research plan payments receivables                 $ 1,000          
Addition to the transaction price 4,000                     4,000    
Option exercise fees                 $ 8,000          
Restated Roche Agreement | Minimum                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Written notice period for termination of agreement                 90 days          
Restated Roche Agreement | Maximum | Research, development and commercial milestone payments                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Amount eligible to receive                 $ 273,000          
Restated Roche Agreement | Maximum | One-time sales-based payments                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Amount eligible to receive                 150,000          
Restated Roche Agreement | Lead series identification achievement                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Upfront fees                 $ 2,000          
Biogen Research and License Agreement                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Research agreement, period                   54 months        
Nonrefundable upfront payment                   $ 45,000        
Revenue recognized that was included in the contract liability at the beginning of the period         $ 8,000 $ 8,000                
Number of development candidates | developmentCandidate         2                  
Biogen Research and License Agreement | Maximum                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Number of targeted protein degradation | protein                   5        
Biogen Research and License Agreement | Maximum | Research and development milestones                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Payment received                   $ 35,000        
Biogen Research and License Agreement | Maximum | One-time sales-based payments                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Payment received                   $ 26,000        
Restated Roche Agreement And Biogen License Agreement                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Transaction price allocated to performance obligation $ 164,700                     $ 164,700